1. Generics Bulletin
  2. >>Leadership

Who’s Hired? Ananth Returns To Teva As New API Chief

As Strides Switches COO And Civica Rx Announces Sterile Injectables Site Manager

 
• By Dave Wallace

Teva has announced that R. Ananthanarayanan – known as Ananth – is to rejoin the company as CEO of its active pharmaceutical ingredients business after taking leading roles at Cipla and Strides in recent years. Meanwhile, Strides has disclosed a change of chief operating officer coming next year, while Civica Rx has named a manager for its sterile injectables operations.

Welcome back spelled out in tiles
R. Ananthanarayanan is returning to Teva • Source: Shutterstock

Teva has announced that its former active pharmaceutical ingredient and biologics operations chief of several years ago, R. Ananthanarayanan, is to rejoin the company as CEO of its Teva API business from 27 November. He will be based out of Teva’s US headquarters in Parsippany, New Jersey.

Ananthanarayanan – also known as Ananth – has served in multiple high-profile roles since leading the former Teva API and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications Generics Bulletin, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Who’s Hired? Stada Picks Biogen’s Biosimilars Chief Henshaw To Lead Specialty Segment

 
• By Dave Wallace

Stada has appointed former Biogen biosimilars head Ian Henshaw as the new leader of its Specialty segment. Meanwhile, Craig Burton has left the AAM for Fresenius Kabi, Australia's GBMA is looking for a new chief executive, and Speranza, Outlook and EuroAPI have announced new appointments.

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe

 
• By Dave Wallace

As Biocon Biologics picks up the latest approvals in Europe for its Stelara biosimilar, Blake Leitch, the firm’s head of Europe, talks to Generics Bulletin about what lies ahead for Biocon and for biosimilars more widely in the region – including tackling the “biosimilar void”.

Finding The Right Leadership In A Fast-Moving Industry: Parsity Group’s Nathan Talks Recruitment

 
• By Dave Wallace

What makes the generics and biosimilars sector unique when it comes to executive talent searches and recruitment? Dan Nathan, founder and managing director of Parsity Group, talks to Generics Bulletin about how the firm operates in the fast-moving global off-patent industry.

More from Generics Bulletin

Water Pressure: How European Industry Is Pushing Back On The UWWTD

 
• By Dave Wallace

Concern continues to build in the European generics industry over the threat posed by the EU’s Urban Wastewater Treatment Directive, which was one of the hottest topics of discussion at Medicines for Europe’s legal and annual conferences. And now, the association has intervened in a legal challenge.

Pertuzumab Leader Henlius Receives EU Accreditation For Production Lines

 
• By Dean Rudge

Shanghai Henlius Biotech has received EMA GMP certification for its HLX14 and HLX11 biosimilar production lines, paving the way for faster market entry in the EU and reinforcing its global manufacturing credentials.

Alvotech Boosts Packaging Abilities With Ivers-Lee Acquisition

 
• By Dean Rudge

Alvotech has acquired long-time partner Ivers-Lee to expand its in-house capacity for assembly and packaging ahead of key planned biosimilar launches in 2025, strengthening operational control and supporting global growth.